The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
Giovanni Biggio - One of the best experts on this subject based on the ideXlab platform.
-
the Muscle Relaxant thiocolchicoside is an antagonist of gabaa receptor function in the central nervous system
Neuropharmacology, 2006Co-Authors: Mario Carta, Giuseppe Talani, Pierluigi De Riu, Enrico Sanna, Gianpietro Sechi, Luca Murru, Paolo Botta, Giovanni BiggioAbstract:Thiocolchicoside (TCC) is used clinically for its Muscle Relaxant, anti-inflammatory, and analgesic properties, and it has been shown to interact with gamma-aminobutyric acid (GABA) type A receptors (GABAARs) and strychnine-sensitive glycine receptors in the rat central nervous system. In contrast to a proposed agonistic action at these two types of inhibitory receptors, pharmacological evidence has shown that, under certain conditions, TCC manifests convulsant activity in animals and humans. We now show that the phasic and tonic GABAAR-mediated currents recorded from Purkinje cells and granule neurons, respectively, in parasagittal cerebellar slices from adult male rats were inhibited by TCC in a concentration-dependent manner. The median inhibitory concentrations of TCC for these effects were approximately 0.15 and approximately 0.9 microM, respectively. TCC did not potentiate GABABR-mediated currents in hippocampal slices, suggesting that its Muscle Relaxant action is not mediated by GABABRs. Intraperitoneal injection of TCC in rats either alone or in combination with negative modulators of GABAergic transmission revealed convulsant and proconvulsant actions of this drug. Our data, consistent with clinical observations of the epileptogenic effect of this compound, suggest that TCC is a potent competitive antagonist of GABAAR function.
-
The Muscle Relaxant thiocolchicoside is an antagonist of GABAA receptor function in the central nervous system
Neuropharmacology, 2006Co-Authors: Mario Carta, Giuseppe Talani, Pierluigi De Riu, Enrico Sanna, Gianpietro Sechi, Luca Murru, Paolo Botta, Giovanni BiggioAbstract:Thiocolchicoside (TCC) is used clinically for its Muscle Relaxant, anti-inflammatory, and analgesic properties, and it has been shown to interact with γ-aminobutyric acid (GABA) type A receptors (GABAARs) and strychnine-sensitive glycine receptors in the rat central nervous system. In contrast to a proposed agonistic action at these two types of inhibitory receptors, pharmacological evidence has shown that, under certain conditions, TCC manifests convulsant activity in animals and humans. We now show that the phasic and tonic GABAAR-mediated currents recorded from Purkinje cells and granule neurons, respectively, in parasagittal cerebellar slices from adult male rats were inhibited by TCC in a concentration-dependent manner. The median inhibitory concentrations of TCC for these effects were ∼0.15 and ∼0.9 μM, respectively. TCC did not potentiate GABABR-mediated currents in hippocampal slices, suggesting that its Muscle Relaxant action is not mediated by GABABRs. Intraperitoneal injection of TCC in rats either alone or in combination with negative modulators of GABAergic transmission revealed convulsant and proconvulsant actions of this drug. Our data, consistent with clinical observations of the epileptogenic effect of this compound, suggest that TCC is a potent competitive antagonist of GABAAR function. © 2006 Elsevier Ltd. All rights reserved.
Mario Carta - One of the best experts on this subject based on the ideXlab platform.
-
the Muscle Relaxant thiocolchicoside is an antagonist of gabaa receptor function in the central nervous system
Neuropharmacology, 2006Co-Authors: Mario Carta, Giuseppe Talani, Pierluigi De Riu, Enrico Sanna, Gianpietro Sechi, Luca Murru, Paolo Botta, Giovanni BiggioAbstract:Thiocolchicoside (TCC) is used clinically for its Muscle Relaxant, anti-inflammatory, and analgesic properties, and it has been shown to interact with gamma-aminobutyric acid (GABA) type A receptors (GABAARs) and strychnine-sensitive glycine receptors in the rat central nervous system. In contrast to a proposed agonistic action at these two types of inhibitory receptors, pharmacological evidence has shown that, under certain conditions, TCC manifests convulsant activity in animals and humans. We now show that the phasic and tonic GABAAR-mediated currents recorded from Purkinje cells and granule neurons, respectively, in parasagittal cerebellar slices from adult male rats were inhibited by TCC in a concentration-dependent manner. The median inhibitory concentrations of TCC for these effects were approximately 0.15 and approximately 0.9 microM, respectively. TCC did not potentiate GABABR-mediated currents in hippocampal slices, suggesting that its Muscle Relaxant action is not mediated by GABABRs. Intraperitoneal injection of TCC in rats either alone or in combination with negative modulators of GABAergic transmission revealed convulsant and proconvulsant actions of this drug. Our data, consistent with clinical observations of the epileptogenic effect of this compound, suggest that TCC is a potent competitive antagonist of GABAAR function.
-
The Muscle Relaxant thiocolchicoside is an antagonist of GABAA receptor function in the central nervous system
Neuropharmacology, 2006Co-Authors: Mario Carta, Giuseppe Talani, Pierluigi De Riu, Enrico Sanna, Gianpietro Sechi, Luca Murru, Paolo Botta, Giovanni BiggioAbstract:Thiocolchicoside (TCC) is used clinically for its Muscle Relaxant, anti-inflammatory, and analgesic properties, and it has been shown to interact with γ-aminobutyric acid (GABA) type A receptors (GABAARs) and strychnine-sensitive glycine receptors in the rat central nervous system. In contrast to a proposed agonistic action at these two types of inhibitory receptors, pharmacological evidence has shown that, under certain conditions, TCC manifests convulsant activity in animals and humans. We now show that the phasic and tonic GABAAR-mediated currents recorded from Purkinje cells and granule neurons, respectively, in parasagittal cerebellar slices from adult male rats were inhibited by TCC in a concentration-dependent manner. The median inhibitory concentrations of TCC for these effects were ∼0.15 and ∼0.9 μM, respectively. TCC did not potentiate GABABR-mediated currents in hippocampal slices, suggesting that its Muscle Relaxant action is not mediated by GABABRs. Intraperitoneal injection of TCC in rats either alone or in combination with negative modulators of GABAergic transmission revealed convulsant and proconvulsant actions of this drug. Our data, consistent with clinical observations of the epileptogenic effect of this compound, suggest that TCC is a potent competitive antagonist of GABAAR function. © 2006 Elsevier Ltd. All rights reserved.
Joanne Mills Garrett - One of the best experts on this subject based on the ideXlab platform.
-
The use of Muscle Relaxant medications in acute low back pain
Spine, 2004Co-Authors: Eric Bernstein, Timothy S. Carey, Joanne Mills GarrettAbstract:STUDY DESIGN: Prospective cohort study. OBJECTIVES: To determine the characteristics of patients who take Muscle Relaxants for back pain after seeking care and to determine the relationship of Muscle Relaxant use with recovery from the episode of low back pain. SUMMARY OF BACKGROUND DATA: Low back pain is a common condition with a generally favorable short-term prognosis. Physicians in the acute setting commonly prescribe Muscle Relaxants. The indications for use and outcomes are not clear. METHODS: We performed a secondary data analysis of a cohort of 1633 patients who sought care from a variety of practitioners (primary care, physician of chiropractic, orthopedic surgeon, Health Maintenance Organization) for low back pain. Patients were enrolled in the physician's office and interviewed at baseline, 2, 4, 8, 12, and 24 weeks. Pain, functional status, medication use, health care utilization, and satisfaction with care were assessed. RESULTS: Muscle Relaxants were used by 49% of patients; among those who sought care from doctors, 64% used Muscle Relaxants. Muscle Relaxant users were more impaired at baseline. Over time, among patients with greater functional status impairment (Roland disability score > 12) at baseline, Muscle Relaxant users had somewhat slower recovery from the episode of back pain. This finding persisted after controlling for baseline functional status, age, worker's compensation status, and use of nonsteroidal inflammatory agents. CONCLUSIONS: Use of Muscle Relaxants was very common among patients with acute low back pain. Muscle Relaxant use was not associated with more rapid functional recovery.
Nazar Ul Islam - One of the best experts on this subject based on the ideXlab platform.
-
antinociceptive Muscle Relaxant and sedative activities of gold nanoparticles generated by methanolic extract of euphorbia milii
BMC Complementary and Alternative Medicine, 2015Co-Authors: Abdur Rauf, Naveed Muhammad, Nazar Ul Islam, Ibrahim Khan, Muhammad Shahid, Mohammad Raza ShahAbstract:Nanotechnology has potential future for enhancing therapeutic efficacy and reducing the unwanted effects of herbal drugs. The biological research on Euphorbia species has been supported by the use of some plants in traditional medicines. Many species of Euphorbia have been reported as having strong sedative and analgesic effects. In the present research work gold nanoparticles of Euphorbia milii methanolic extract (Au-EM) were synthesized, characterized and tested for antinociceptive, Muscle Relaxant and sedative activities. Au-EM was prepared by stirring 1 mM warm trihydrated tetrachloroaurate solution with E. milii methanolic extract without using any external reducing agents. The gold nanoparticles were characterized by UV-Visible spectroscopy, infrared spectrophotometery, atomic force microscopy and scanning electron microscopy while their stability was evaluated against varying pH and different volumes of sodium chloride (NaCl). The metal sensing capacity of Au-EM was tested towards cobalt, copper, lead, mercury and nickel. Au-EM was evaluated in BALB/c mice at a dose of 10 and 20 mg/kg for antinociceptive, Muscle Relaxant and sedative activities in comparison with the crude E. milii methanolic extract. Au-EM showed remarkable stability in different NaCl and pH solutions. Au-EM produced significant (P < 0.01) antinociceptive effect at doses of 10 and 20 mg/kg as compared to the crude E. milii methanolic extract. In the rotarod test, Au-EM showed significant Muscle Relaxant effect at 10 mg/kg (P < 0.05) and 20 mg/kg (P < 0.01) after 30, 60 and 90 min. In an open field test significant sedative effect (P < 0.05) of Au-EM was observed at 10 and 20 mg/kg. Moreover significant detection sensitivity was demonstrated towards all the tested heavy metals. These results concluded that the gold nanoparticles improved the potency of E. milii methanolic extract and exhibited significant analgesic, Muscle Relaxant and sedative properties. The significant metals sensing ability and enhanced stability in different NaCl and pH solutions may enable us to explore different formulations of E. milii gold nanoparticles for potentially effective and safe nano-herbal therapy.
Wentao Dai - One of the best experts on this subject based on the ideXlab platform.
-
magnesium sulfate enhances non depolarizing Muscle Relaxant vecuronium action at adult Muscle type nicotinic acetylcholine receptor in vitro
Acta Pharmacologica Sinica, 2011Co-Authors: Hong Wang, Qisheng Liang, Lanren Cheng, Wentao DaiAbstract:Magnesium sulfate enhances non-depolarizing Muscle Relaxant vecuronium action at adult Muscle-type nicotinic acetylcholine receptor in vitro
